ImmunityBio, Inc. (IBRX) — Available-Data Snapshot

We don't publish a discounted-cash-flow fair value for ImmunityBio, Inc. (IBRX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, IBRX trades at a recent price of $7.11, a market capitalisation of about $7,535,436,288, sitting 49% of the way up its 52-week range ($1.95–$12.43), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing IBRX's trading multiples against a sector benchmark. Here that gives P/S of 45.5× (richer than the peer median of 6.8×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

Finally, a price-based read — explicitly not a valuation. IBRX is in a mixed trend, trading -42.8% from its 52-week high. Over the past year the stock is +299.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.